The Company was incorporated.
The Company completed our Series A financing and raised a total of USD10 million in June.
The Company completed a single-center feasibility clinical trial on ten patients in China for TaurusOne® in August.
The Company started the multi-center confirmatory clinical trial in China for TaurusOne® in September.
Achieva Medical became our subsidiary through a share swap agreement in March.
The Company completed our Series B financing and raised approximately USD29 million in February.
The Company obtained the NMPA Registration Certificate for our Yibida® Guiding Catheter in May.
The Company completed our Series C financing and raised a total of USD25 million in September.
The Company launched sales of our second-generation Presgo® Detachable Coil in October.
The Company completed our Series C-1 financing and raised a total of USD45 million in December.
The Company initiated the clinical trial for TaurusEliteTM, our second-generation TAVR device, in December.